Venturi Wealth Management LLC Has $129,000 Stock Position in Fresenius Medical Care AG (NYSE:FMS)

Venturi Wealth Management LLC raised its position in Fresenius Medical Care AG (NYSE:FMS) by 8.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,700 shares of the company’s stock after acquiring an additional 441 shares during the period. Venturi Wealth Management LLC’s holdings in Fresenius Medical Care were worth $129,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Verition Fund Management LLC acquired a new position in Fresenius Medical Care in the 3rd quarter valued at approximately $237,000. JPMorgan Chase & Co. raised its holdings in Fresenius Medical Care by 18.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,902 shares of the company’s stock valued at $211,000 after acquiring an additional 1,528 shares in the last quarter. ABC Arbitrage SA acquired a new position in Fresenius Medical Care in the 4th quarter valued at approximately $4,215,000. Charles Schwab Investment Management Inc. grew its stake in shares of Fresenius Medical Care by 11.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 22,161 shares of the company’s stock valued at $472,000 after purchasing an additional 2,233 shares during the period. Finally, MML Investors Services LLC grew its stake in shares of Fresenius Medical Care by 5.3% in the 3rd quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock valued at $320,000 after purchasing an additional 753 shares during the period. Institutional investors and hedge funds own 8.37% of the company’s stock.

Analysts Set New Price Targets

FMS has been the topic of several analyst reports. StockNews.com upgraded Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Truist Financial upped their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Berenberg Bank initiated coverage on Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price objective on the stock. Finally, Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd.

Fresenius Medical Care Stock Up 0.6 %

NYSE FMS opened at $23.09 on Friday. The firm has a market cap of $13.55 billion, a PE ratio of 19.08, a price-to-earnings-growth ratio of 0.76 and a beta of 0.93. Fresenius Medical Care AG has a one year low of $17.93 and a one year high of $25.25. The stock’s 50 day simple moving average is $23.41 and its 200 day simple moving average is $21.68. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.